Impact on Quality of Life and Burden of Disease in Adults With Herpes Zoster

NCT ID: NCT06667245

Last Updated: 2024-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

357 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-04

Study Completion Date

2026-11-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Title: Impact on quality of life and disease burden in adults with herpes zoster

Prospective cohort study for the primary objective and the secondary objectives (1 and 2) and retrospective cohort study for the secondary objective 3.

Disease or disorder under study: Patients with a herpes zoster (HZ) diagnosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Impact on quality of life and disease burden in adults with herpes zoster Contents

HYPOTHESIS AND OBJECTIVES OF THE STUDY 3.1 Hypothesis: Herpes zoster significantly affects the quality of life of those who suffer from it with a high disease burden.

3.2 Primary outcomes: To measure the quality of life of patients with a history of herpes zoster who attend the immunization unit of the Fundación Jiménez Díaz University Hospital.

3.3 Secondary outcomes

1. Evaluating the quality of life according to the location of the zoster (postherpetic neuralgia, ophthalmic zoster, etc.)
2. Evaluating the effectiveness of the vaccine against herpes zoster in terms of number of episodes, severity and quality of life.
3. Evaluating the economic impact and disease burden in terms of morbidity and mortality in adult with herpes zoster

TYPE OF STUDY AND DESIGN

Prospective cohort study for the primary objective and the secondary objectives (1 and 2) and retrospective cohort study for the secondary objective 3.

Disease or disorder under study: Patients with a herpes zoster (HZ) diagnosis.

SUBJECT SELECTION 5.1 Prospective cohort study Inclusion criteria Patients \> 18 years of age who are to be immunised against HZ

Exclusion criteria:

* Pregnant women
* Patients with altered level of consciousness (dementia and others) who do not complete the questionnaires
* Patients who do not wish to participate in the study 5.2 Retrospective cohort study Inclusion criteria
* Adults over 18 years of age with a diagnosis of HZ in the CMBD from 2012 to 2023 at the Jiménez Díaz Foundation. Since the international classification of diseases changed from ICD 9 to ICD 10 in 2016, the codes to be used for the inclusion of patients in the study are described below.

ICD 9 053 Herpes zoster Includes:

Herpes zoster Zone 053.0 With meningitis 053.1 With other central nervous system complications 053.10 With unspecified nervous system complications 053.11 Geniculate herpes zoster or Herpetic geniculate ganglionitis 053.12 Postherpetic trigeminal neuralgia 053.13 Postherpetic polyneuropathy 053.14 Herpes zoster myelitis 053.19 Other 053.2 With ophthalmic complications 053.20 Herpes zoster dermatitis of eyelid or Herpes zoster ophthalmicus 053.21 Herpes zoster keraconjunctivitis 053.22 Herpes zoster iridocyclitis 053.29 Other 053.7 With other complications specific 053.71 Otitis externa due to herpes zoster 053.79 Other 053.8 With unspecified complications 053.9 Herpes zoster without complication Herpes zoster NOS ICD 10 B02 Herpes zoster Includes: - herpes - zone B02.0 Encephalitis due to herpes zoster Meningoencephalitis due to herpes zoster B02.1 Meningitis due to herpes zoster B02.2 Herpes zoster with other nervous system involvement B02.21 Postherpetic geniculate ganglionitis B02.22 Postherpetic trigeminal neuralgia B02.23 Postherpetic polyneuropathy B.02.24 Postherpetic myelitis or Herpes zoster myelitis B02.29 Other postherpetic nervous system involvement or Postherpetic radiculopathy B02.3 Ocular herpes zoster B02.30 Ocular herpes zoster, unspecified B02.31 Herpes zoster conjunctivitis B02.32 Herpes zoster iridocyclitis B02.33 Herpes zoster keratitis or Herpes zoster keratoconjunctivitis B02.34 Herpes zoster scleritis B02.39 Other herpes zoster eye diseases or Herpes zoster blepharitis B02.7 Disseminated herpes zoster B02.8 Herpes zoster with other complications Herpes zoster otitis externa B02.9 Uncomplicated herpes zoster Herpes zoster

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Herpes Zoster Quality of Life Immunization; Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients > 18 years old who are going to be immunized against HZ

Patients \> 18 years old who are going to be immunized against HZ

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

ICD 9 053 Herpes zoster

Includes:

* Herpes zoster
* Zone 053.0 With meningitis 053.1 With other central nervous system complications
* 053.10 With unspecified nervous system complications
* 053.11 Geniculate herpes zoster or Herpetic geniculate ganglionitis
* 053.12 Postherpetic trigeminal neuralgia
* 053.13 Postherpetic polyneuropathy
* 053.14 Herpes zoster myelitis
* 053.19 Other 053.2 With ophthalmic complications
* 053.20 Herpes zoster dermatitis of eyelid or Herpes zoster ophthalmicus
* 053.21 Herpes zoster keratoconjunctivitis
* 053.22 Herpes zoster iridocyclitis zoster
* 053.29 Other 053.7 With other specific complications
* 053.71 Otitis externa due to herpes zoster
* 053.79 Other 053.8 With unspecified complications 053.9 Herpes zoster without complication Herpes zoster NOS ICD 10 B02 Herpes zoster

Includes:

* herpes
* zona B02.0 Encephalitis due to herpes zoster Meningoencephalitis due to zoster B02.1 Meningitis due to herpes zoster B02.2 Herpes zoster with other nervous system involvement
* B02.21 Postherpetic geniculate ganglionitis
* B02.22 Postherpetic trigeminal neuralgia
* B02.23 Postherpetic polyneuropathy
* B.02.24 Myelitis Postherpetic myelitis
* B02.29 Other postherpetic nervous system involvement
* B02.3 Ocular herpes zoster
* B02.30 Ocular herpes zoster, unspecified
* B02.31 Herpes zoster conjunctivitis
* B02.32 Herpes zoster iridocyclitis
* B02.33 Herpes zoster keratitis
* B02.34 Herpes zoster scleritis
* B02.39 Other herpes zoster eye disease
* B02.7 Disseminated herpes zoster
* B02.8 Herpes zoster with other complications
* B02.9 Uncomplicated herpes zoster
* B02.39 Herpes zoster otitis externa NEOM

Exclusion Criteria

* Pregnant women
* Patients with altered level of consciousness (dementia and others) who do not complete the questionnaires

Patients who are vaccinated against HZV
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitario Fundación Jiménez Díaz

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

ALBA VEGA, PhD investigator

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

https://pubmed.ncbi.nlm.nih.gov/35215786/

Patil A. Goldust M. Wollina U. Herpes zoster: A Review of Clinical Manifestations and Management. Viruses. \[Internet\]. 2022. \[Consultado 18 Feb 2024\]; 14(2)

https://pubmed.ncbi.nlm.nih.gov/37580664/

Kain A., Tizek L., Wecker H., Wallnöfer F., Biedermann T., Zink A. Evaluating public interest in herpes zoster in Germany by leveraging the internet: a retrospective search data analysis. BMC Public Health. \[Internet\]. 2023. \[Consultado 29 Mar 2024\]; 2

https://www.sanidad.gob.es/biblioPublic/publicaciones/recursos_propios/resp/revista_cdrom/VOL95/ORIGINALES/RS95C_202106088.pdf

Masa Calles J. López Perca N. Vila Cordero B. Carmona R. Vigilancia y epidemiología del herpes zóster en España. RevEsp Salud Pública.\[Internet\]. 2021. \[Consultado 18 Feb 2024\]; 95. (e1-13).

https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/archivos%20A-Z/HERPES%20ZOSTER/Informe_HZ_Espa%C3%B1a_1998-2018.pdf

Centro Nacional de Epidemiología. CIBERESP. Instituto de Salud Carlos III. Informe epidemiológico sobre la situación del Herpes Zóster en España. \[Internet\]. 2020. \[Consultado 18 Feb 2024\].

https://pubmed.ncbi.nlm.nih.gov/34520327/

Patkia A., Vorab A., Parikh R., Kolhapure S., Agrawal A., Dash R. Herpes zoster in outpatient departments of healthcare centers in India: a review of literatura. Human vaccines\&immunotherapeutics. \[Internet\]. 2021. \[Consultado 29 Mar 2024\].

https://pubmed.ncbi.nlm.nih.gov/36851652/

Ralph Tayyar R., Ho D. Herpes Simplex Virus and Varicella Zoster Virus Infections in Cancer Patients. Viruses. \[Internet\]. 2023. \[Consultado 28 Mar 2024\];15, 439.

https://pubmed.ncbi.nlm.nih.gov/34994924/

Van Oorschot D., McGirr A., Goulet P., Koochaki P., Pratiwadi R., Shah S., Curran D. A Cross-Sectional Concept Elicitation Study to Understand the Impact of Herpes Zoster on Patients' Health-Related Quality of Life. InfectDisTher. \[Internet\]. 2022.

https://pubmed.ncbi.nlm.nih.gov/36032345/

Sollie M., Jepsen P., Sørensen, JA. (2022). Patient-reported quality of life in patients suffering from acute herpes zoster-a systematic review with meta-analysis. British journal of pain. \[Internet\]. 2022. \[Consultado 28 Mar 2024\]; 15 16(4), 404-419.

https://pubmed.ncbi.nlm.nih.gov/34013498/

Díez Domingo J., Curran D., Cambronero MR., Garcia Martinez JA., Matthews S. Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study. Advances in therapy. \[Internet\]. 2021. \[C

https://pubmed.ncbi.nlm.nih.gov/30793003/

Matthews S., De Maria A., Passamonti M.,Ristori G., Loiacono I., Puggina A., Curran D. The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy. Open ForumInfectDis. \[

https://pubmed.ncbi.nlm.nih.gov/38124774/

Zhao D, Suo L., Lu L., Pan J., Peng X., Wang Y., Pang X. Impact of herpes zoster and post-herpetic neuralgia on health-relate. Vaccine X. \[Internet\]. 2023. \[Consultado 28 Mar 2024\]; 15, 100415.

https://pubmed.ncbi.nlm.nih.gov/31462457/

Curran D., Hunjan M., El Ghachi A., El-Hahi Y., Bianco V., Ferreira G. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis. BMJ Open. \[Interne

https://pubmed.ncbi.nlm.nih.gov/36504661/

Chen L., Li J., Liu H., Yang P., Zuo Y., Ye L. Interventions for zoster-associated pain: A retrospective study based on the clinical database.Front Neurol. \[Internet\]. 2022. \[Consultado 29 Mar 2024\];13:1056171.

https://pubmed.ncbi.nlm.nih.gov/31151330/

Lin CS., Lin YC., Lao HC., Chen CC. Interventional Treatments for Postherpetic Neuralgia: A Systematic Review. Pain Physician. \[Internet\]. 2019. \[Consultado 28 Mar 2024\]; 22,209-228.

https://pubmed.ncbi.nlm.nih.gov/33894728/

Zeng F., Wang M., Zhang D. Cost-effectiveness analysis of 5% lidocaine-medicated plaster compared with pregabalin for the treatment of post-herpetic neuralgia in China.Pain and therapy. \[Internet\]. 2021. \[Consultado 30 Mar 2024\]; 10(1), 675-689.

https://pubmed.ncbi.nlm.nih.gov/36032345/

Sollie M., Jepsen P., Sorensen JA. Patient-reported quality of life in patients suffering from acute herpes zoster-a systematic review with meta-analysis. British Journal of Pain. \[Internet\]. 2022. \[Consultado 18 Feb 2024\]; 16(4) 404-419.

https://pubmed.ncbi.nlm.nih.gov/35181196/

Hideo Hashizumea H., NakataniaE. ,Satoa Y., Gotoc H. , Yagic H., Miyachi Y. A new susceptibility index to predict the risk of severe herpes zoster-associated pain: A Japanese regional population-based cohort study, the Shizuoka study. Journal of Derma

https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/archivos%20A-Z/HERPES%20ZOSTER/Informe_HZ_Espa%C3%B1a_1998-2018.pdf

Centro Nacional de Epidemiología. CIBERESP. Instituto de Salud Carlos III. Informe epidemiológico sobre la situación del Herpes Zóster en España. \[Internet\]. Madrid; 2020. \[Consultado 18 Feb 2024\].

https://pubmed.ncbi.nlm.nih.gov/23055426/

Sicras-Mainar A., Navarro-Artieda R., Ibanez-Nolla J., Perez-Ronco J. Incidence, resource use and costs associated with postherpetic neuralgia: a population-based retrospective study. Rev Neurol. . \[Internet\].2012\[Consultado 10 Abr 2024\]; 55:449-461.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

V1.0_03.04.24

Identifier Type: -

Identifier Source: org_study_id